乳腺癌垂体转移的临床表现与病理特征:病例报告及文献系统综述
本文报告一例57岁女性乳腺癌术后16年发生垂体孤立性转移的病例,术前误诊为垂体腺瘤,经神经内镜辅助经鼻蝶窦入路完整切除,病理及免疫组化确诊为乳腺癌垂体转移,术后视力改善且随访1年无复发。作者结合文献系统综述指出垂体转移罕见、无病理难以与垂体腺瘤鉴别,手术为首选治疗,并应结合放化疗及内分泌治疗。
要点
- 乳腺癌术后多年出现鞍区占位时应警惕垂体转移可能。
- 垂体转移术前难以与垂体腺瘤鉴别,确诊依赖病理与免疫组化。
- 手术是垂体转移的首选治疗,术后需结合放化疗和内分泌治疗。
核心结论
- 垂体转移罕见,无病理诊断难以与垂体腺瘤鉴别;手术是首选治疗,并应结合放化疗与内分泌治疗,依据免疫组化结果制定个体化方案。
研究设计与样本
- 病例报告:一例57岁女性乳腺癌根治术后16年发生垂体孤立性转移,行神经内镜辅助单鼻孔经蝶窦入路肿瘤切除术。
- 文献系统综述:作者对相关文献进行了系统综述,具体检索范围原文未报告。
主要发现
- 患者因视力模糊1年、发作性头痛1月入院,MRI示鞍区实性肿块伴不均匀强化,术前诊断为垂体腺瘤。
- 术中见粉白色质硬肿瘤、血供丰富、与正常垂体组织边界不清,实现完整切除。
- 免疫组化细胞角蛋白、Ki-67抗原、雌激素受体、孕激素受体及催乳素诱导蛋白阳性,spalt样转录因子4、乳腺球蛋白及糖蛋白激素α亚基阴性,确诊为乳腺癌垂体转移。
- 术后患者视力显著改善,随访1年未见复发。
临床怎么用
- 作者认为手术是垂体转移的首选治疗,并应结合放疗、化疗及内分泌治疗,依据免疫组化结果制定个体化方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is rare for breast carcinoma to metastasize to the pituitary gland; this finding indicates extensive metastasis of the primary tumor. CASE DESCRIPTION: Herein, we present a 57-year-old patient with pituitary gland metastasis from breast cancer that was treated with extensive radical mastectomy 16 years prior. The pituitary was the sole site of metastasis. The patient was admitted with the chief complaint of blurred vision for 1 year and episodic headaches for 1 month. Magnetic resonance imaging revealed a solid mass in the sellar region with heterogenous contrast enhancement. The preoperative diagnosis was a pituitary adenoma. Neuroendoscopy-assisted tumor resection was conducted through a single-nostril sphenoid sinus approach. A pinkish-white, firm neoplasm was found, with an abundant blood supply and an indistinct boundary between the neoplasm and normal pituitary tissue; complete resection was achieved. The results of immunohistochemical analysis were positive for cytokeratin, Ki-67antigen, estrogen receptors, progesterone receptors, and prolactin-induced protein. The neoplasm was negative for spalt-like transcription factor 4, mammaglobin, and the alpha subunit of the glycoprotein hormones. These results were used to reach a final diagnosis of pituitary gland metastasis from a primary breast carcinoma. The patient's vision improved significantly after surgery, and no recurrence was detected during 1 year of follow-up. CONCLUSIONS: Pituitary gland metastasis is rare and difficult to differentiate from a pituitary adenoma without a pathologic diagnosis. Surgery is the first choice for treatment. Surgery, radiotherapy, and chemotherapy are combined with endocrine therapy to tailor treatment to the results of immunohistochemistry.
引用
- Cai H, Liu W, Feng T, et al. Clinical Presentation and Pathologic Characteristics of Pituitary Metastasis from Breast Carcinoma: Cases and a Systematic Review of the Literature. World Neurosurg. 2019. PMID: 30630045. doi:10.1016/j.wneu.2018.12.126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。